These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 28682795)

  • 1. Genetics of pancreatic cyst-cancer progression: standing on the shoulders of giants.
    Giri B; Sethi V; Dudeja V; Banerjee S; Livingstone A; Saluja A
    Curr Opin Gastroenterol; 2017 Sep; 33(5):404-410. PubMed ID: 28682795
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genomics of pancreatic ductal adenocarcinoma.
    Pilarsky C; Grutzmann R
    Hepatobiliary Pancreat Dis Int; 2014 Aug; 13(4):381-5. PubMed ID: 25100122
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Genetic Diversity of Pancreatic Ductal Adenocarcinoma and Opportunities for Precision Medicine.
    Knudsen ES; O'Reilly EM; Brody JR; Witkiewicz AK
    Gastroenterology; 2016 Jan; 150(1):48-63. PubMed ID: 26385075
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can we move towards personalised pancreatic cancer therapy?
    Jamieson NB; Chang DK; Grimmond SM; Biankin AV
    Expert Rev Gastroenterol Hepatol; 2014 May; 8(4):335-8. PubMed ID: 24702631
    [No Abstract]   [Full Text] [Related]  

  • 5. The genetics of ductal adenocarcinoma of the pancreas in the year 2020: dramatic progress, but far to go.
    Thompson ED; Roberts NJ; Wood LD; Eshleman JR; Goggins MG; Kern SE; Klein AP; Hruban RH
    Mod Pathol; 2020 Dec; 33(12):2544-2563. PubMed ID: 32704031
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetics of Familial and Sporadic Pancreatic Cancer.
    Wood LD; Yurgelun MB; Goggins MG
    Gastroenterology; 2019 May; 156(7):2041-2055. PubMed ID: 30660730
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular pathogenesis of pancreatic ductal adenocarcinoma and clinical implications.
    Magee CJ; Greenhalf W; Howes N; Ghaneh P; Neoptolemos JP
    Surg Oncol; 2001; 10(1-2):1-23. PubMed ID: 11719025
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Molecular Diagnostics in the Evaluation of Pancreatic Cysts.
    Theisen BK; Wald AI; Singhi AD
    Surg Pathol Clin; 2016 Sep; 9(3):441-56. PubMed ID: 27523971
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Next generation sequencing of pancreatic ductal adenocarcinoma: right or wrong?
    Connor AA; Gallinger S
    Expert Rev Gastroenterol Hepatol; 2017 Jul; 11(7):683-694. PubMed ID: 28460572
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular landscape of pancreatic cancer: challenges and clinical implications.
    Kyrochristos ID; Ziogas DE; Glantzounis GK; Roukos DH
    Future Oncol; 2017 Dec; 13(30):2741-2744. PubMed ID: 29182377
    [No Abstract]   [Full Text] [Related]  

  • 11. Update on the management of pancreatic cancer: surgery is not enough.
    Ansari D; Gustafsson A; Andersson R
    World J Gastroenterol; 2015 Mar; 21(11):3157-65. PubMed ID: 25805920
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cytogenetic, Molecular, and Translational Applications in Pancreatic Ductal Adenocarcinoma: Current Evidence and Future Concepts.
    Malla RR; Kumari S
    Crit Rev Oncog; 2019; 24(2):119-132. PubMed ID: 31679207
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting KRAS for diagnosis, prognosis, and treatment of pancreatic cancer: Hopes and realities.
    Bournet B; Buscail C; Muscari F; Cordelier P; Buscail L
    Eur J Cancer; 2016 Feb; 54():75-83. PubMed ID: 26735353
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pancreatic biomarkers: could they be the answer?
    Lamarca A; Feliu J
    World J Gastroenterol; 2014 Jun; 20(24):7819-29. PubMed ID: 24976720
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Updates and Critical Evaluation on Novel Biomarkers for the Malignant Progression of Intraductal Papillary Mucinous Neoplasms of the Pancreas.
    Moris D; Damaskos C; Spartalis E; Papalampros A; Vernadakis S; Dimitroulis D; Griniatsos J; Felekouras E; Nikiteas N
    Anticancer Res; 2017 May; 37(5):2185-2194. PubMed ID: 28476781
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Translational genomics in pancreatic ductal adenocarcinoma: A review with re-analysis of TCGA dataset.
    Ho J; Li X; Zhang L; Liang Y; Hu W; Yau JCW; Chan H; Gin T; Chan MTV; Tse G; Wu WKK
    Semin Cancer Biol; 2019 Apr; 55():70-77. PubMed ID: 29705685
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Organoid models for translational pancreatic cancer research.
    Tiriac H; Plenker D; Baker LA; Tuveson DA
    Curr Opin Genet Dev; 2019 Feb; 54():7-11. PubMed ID: 30844513
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
    Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
    World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pancreatic cancer development and progression: remodeling the model.
    Real FX; Cibrián-Uhalte E; Martinelli P
    Gastroenterology; 2008 Sep; 135(3):724-8. PubMed ID: 18692502
    [No Abstract]   [Full Text] [Related]  

  • 20. MYC in pancreatic cancer: novel mechanistic insights and their translation into therapeutic strategies.
    Hessmann E; Schneider G; Ellenrieder V; Siveke JT
    Oncogene; 2016 Mar; 35(13):1609-18. PubMed ID: 26119937
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.